KRAS and colorectal neoplasm: This combination therapy failed todelay tumour growth (Fig. 1D, E) and did not lead to an increase in thesurvival of tumour-bearing mice (Fig. 1F).It has previously been shown that MEK inhibition enhances anti-tumour immunityand synergises with anti-PD-L1 in KRAS-mutant CT26 colorectal tumours (17).